Rodin, Gary http://orcid.org/0000-0002-6626-6974
Malfitano, Carmine
Rydall, Anne
Schimmer, Aaron
Marmar, Charles M.
Mah, Kenneth
Lo, Christopher
Nissim, Rinat
Zimmermann, Camilla
Funding for this research was provided by:
Canadian Cancer Society Research Institute (702603; G. Rodin, C. Zimmermann, Co-PIs)
Princess Margaret Cancer Foundation (N/A)
Princess Margaret Cancer Centre, University Health Network (N/A)
Ontario Ministry of Health and Long-Term Care (N/A)
Article History
Received: 3 October 2018
Accepted: 27 February 2019
First Online: 17 April 2019
Compliance with ethical standards
: This pilot trial received approval from the University Health Network (UHN) Research Ethics Board (REB No. 13–6631-CE) and was monitored by the UHN Data Safety Monitoring Board. Informed consent was obtained from all individual participants included in the study. The trial was registered with ExternalRef removed (Identifier: NCT02353559).
: AS reports personal fees and grants outside this submitted work from Novartis, Takeda Pharmaceuticals, Otsuka Pharmaceutical, Jazz Pharmaceuticals, Medivir, and Abbvie. The remaining authors declare no conflicts of interest.
: The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The Co-Principal Investigators had full access to all study data and had final responsibility for the decision to submit for publication. They agree to allow the journal to review the data if requested. This manuscript contains original material.